Pulike Biological Engineering Inc
SSE:603566
Balance Sheet
Balance Sheet Decomposition
Pulike Biological Engineering Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 681.1m |
Receivables | 379.4m |
Other Current Assets | 207.1m |
Non-Current Assets | 1.8B |
Long-Term Investments | 326.9m |
PP&E | 1.2B |
Intangibles | 297m |
Other Non-Current Assets | 43.2m |
Balance Sheet
Pulike Biological Engineering Inc
Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
391
|
429
|
250
|
438
|
283
|
240
|
165
|
282
|
312
|
201
|
|
Cash |
0
|
0
|
0
|
0
|
0
|
0
|
165
|
282
|
312
|
201
|
|
Cash Equivalents |
391
|
429
|
250
|
438
|
283
|
240
|
0
|
0
|
0
|
0
|
|
Short-Term Investments |
400
|
515
|
700
|
295
|
319
|
266
|
75
|
691
|
408
|
480
|
|
Total Receivables |
112
|
118
|
115
|
150
|
169
|
215
|
310
|
507
|
490
|
379
|
|
Accounts Receivables |
109
|
103
|
109
|
141
|
129
|
205
|
292
|
482
|
439
|
364
|
|
Other Receivables |
3
|
15
|
7
|
9
|
40
|
10
|
18
|
25
|
51
|
16
|
|
Inventory |
60
|
62
|
71
|
97
|
118
|
134
|
171
|
192
|
184
|
193
|
|
Other Current Assets |
3
|
2
|
15
|
23
|
23
|
25
|
14
|
22
|
17
|
15
|
|
Total Current Assets |
966
|
1 125
|
1 152
|
1 003
|
912
|
880
|
733
|
1 683
|
1 409
|
1 268
|
|
PP&E Net |
299
|
353
|
369
|
367
|
395
|
466
|
652
|
950
|
1 175
|
1 163
|
|
PP&E Gross |
299
|
353
|
369
|
367
|
395
|
466
|
652
|
950
|
1 175
|
1 163
|
|
Accumulated Depreciation |
140
|
163
|
192
|
223
|
285
|
302
|
324
|
375
|
447
|
506
|
|
Intangible Assets |
231
|
215
|
208
|
220
|
220
|
223
|
276
|
286
|
283
|
279
|
|
Goodwill |
0
|
0
|
0
|
0
|
18
|
18
|
18
|
18
|
18
|
18
|
|
Long-Term Investments |
7
|
42
|
59
|
290
|
321
|
391
|
418
|
383
|
340
|
327
|
|
Other Long-Term Assets |
1
|
2
|
18
|
23
|
40
|
52
|
71
|
75
|
37
|
43
|
|
Other Assets |
0
|
0
|
0
|
0
|
18
|
18
|
18
|
18
|
18
|
18
|
|
Total Assets |
1 504
N/A
|
1 737
+16%
|
1 805
+4%
|
1 903
+5%
|
1 906
+0%
|
2 029
+6%
|
2 168
+7%
|
3 396
+57%
|
3 262
-4%
|
3 097
-5%
|
|
Liabilities | |||||||||||
Accounts Payable |
21
|
28
|
29
|
43
|
39
|
45
|
49
|
123
|
110
|
110
|
|
Accrued Liabilities |
13
|
19
|
27
|
37
|
43
|
52
|
60
|
70
|
69
|
67
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
55
|
35
|
19
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Other Current Liabilities |
108
|
177
|
151
|
158
|
132
|
193
|
237
|
307
|
294
|
237
|
|
Total Current Liabilities |
142
|
224
|
207
|
238
|
214
|
290
|
346
|
556
|
508
|
434
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
0
|
|
Deferred Income Tax |
0
|
0
|
0
|
2
|
7
|
11
|
15
|
25
|
8
|
6
|
|
Other Liabilities |
24
|
32
|
30
|
28
|
27
|
18
|
7
|
8
|
22
|
31
|
|
Total Liabilities |
167
N/A
|
256
+54%
|
236
-8%
|
268
+13%
|
247
-8%
|
319
+29%
|
368
+15%
|
592
+61%
|
538
-9%
|
471
-12%
|
|
Equity | |||||||||||
Common Stock |
160
|
324
|
324
|
324
|
322
|
322
|
321
|
353
|
353
|
346
|
|
Retained Earnings |
604
|
744
|
794
|
865
|
888
|
1 053
|
1 139
|
1 239
|
1 188
|
1 143
|
|
Additional Paid In Capital |
573
|
459
|
478
|
474
|
449
|
469
|
473
|
1 346
|
1 324
|
1 197
|
|
Treasury Stock |
0
|
46
|
27
|
27
|
0
|
134
|
134
|
134
|
141
|
60
|
|
Total Equity |
1 337
N/A
|
1 481
+11%
|
1 569
+6%
|
1 636
+4%
|
1 658
+1%
|
1 710
+3%
|
1 800
+5%
|
2 804
+56%
|
2 724
-3%
|
2 626
-4%
|
|
Total Liabilities & Equity |
1 504
N/A
|
1 737
+16%
|
1 805
+4%
|
1 903
+5%
|
1 906
+0%
|
2 029
+6%
|
2 168
+7%
|
3 396
+57%
|
3 262
-4%
|
3 097
-5%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
320
|
320
|
324
|
324
|
322
|
322
|
315
|
346
|
346
|
342
|